Bar press durations as a reliable and robust measure of frustration-related operant behavior: Sensitivity to incentive downshift and dose-response paradigms.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 25 09 2023
accepted: 05 12 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: epublish

Résumé

In humans, frustrating experiences are known to trigger relapse events and individuals with higher frustration intolerance show increased risk of developing substance use disorders (SUDs). Despite this clear relationship, frustration-related behavior is seldom studied concurrently with self-administration behavior in rodent models. A major obstacle has been the lack of robust, quantitative assays of frustration-related operant behavior thus far. In previous work, we identified increased bar press (BP) durations in response to frustrating conditions in rats self-administering natural or drug rewards. Here, to propose BP durations as a measure of frustration-related behavior, we conducted an operant successive negative contrast (oSNC) study and found that increases in BP durations are observed in the absence of increased effort, providing evidence that this is a psychological phenomenon. Moreover, we assess the viability of widespread use of BP duration measurements as a behavioral tool by quantifying performance as it pertains to sensitivity, robustness, replicability, and sex differences. We conclude that increases in BP durations are a highly sensitive psychological response to frustrating conditions and that this measure is robust, replicable, and applicable to both sexes.

Identifiants

pubmed: 38127939
doi: 10.1371/journal.pone.0296090
pii: PONE-D-23-31203
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0296090

Informations de copyright

Copyright: © 2023 Mármol Contreras et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Yorkiris Mármol Contreras (Y)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Tileena E S Vasquez (TES)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Poonam Shah (P)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Kelsey Payne (K)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Jessica Di Re (J)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Fernanda Laezza (F)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Thomas A Green (TA)

Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Center for Addiction Sciences and Therapeutics, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Mental Health Research Group, The University of Texas Medical Branch, Galveston, Texas, United States of America.

Classifications MeSH